These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21163238)

  • 1. Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas.
    Arratibel-Echarren I; Albright K; Dalmau J; Rosenfeld MR
    Neurologia; 2011 Mar; 26(2):74-80. PubMed ID: 21163238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
    Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab as salvage therapy for progressive brain stem gliomas.
    Reithmeier T; Lopez WO; Spehl TS; Nguyen T; Mader I; Nikkhah G; Pinsker MO
    Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
    Narayana A; Golfinos JG; Fischer I; Raza S; Kelly P; Parker E; Knopp EA; Medabalmi P; Zagzag D; Eagan P; Gruber ML
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):383-9. PubMed ID: 18793954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
    Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
    Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
    Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.
    Lubelski D; Abdullah KG; Weil RJ; Marko NF
    J Neurooncol; 2013 Dec; 115(3):317-22. PubMed ID: 24005770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bevacizumab for the treatment of cerebral radionecrosis].
    Gronier S; Bourg V; Frenay M; Cohen M; Mondot L; Thomas P; Lebrun C
    Rev Neurol (Paris); 2011 Apr; 167(4):331-6. PubMed ID: 21420137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 14. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Chamberlain MC
    Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience.
    Sadraei NH; Dahiya S; Chao ST; Murphy ES; Osei-Boateng K; Xie H; Suh JH; Peereboom DM; Stevens GH; Ahluwalia MS
    Am J Clin Oncol; 2015 Jun; 38(3):304-10. PubMed ID: 23799286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
    Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
    Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in the treatment of high-grade gliomas: an overview.
    Kunnakkat S; Narayana A
    Angiogenesis; 2011 Dec; 14(4):423-30. PubMed ID: 21858651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in high-grade gliomas: past, present, and future.
    Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.